Feedback
Settings

Settings

Goto Application

446,831 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 44,684
1.WO/2026/102237ARTIFICIAL EXPRESSION CONSTRUCTS FOR MODULATING GENE EXPRESSION IN ASTROCYTES FOR THE ASSESSMENT AND/OR TREATMENT OF EPILEPTIC DISORDERS
WO - 15.05.2026
Int.Class C12N 15/864
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
864Parvoviral vectors
 Appl.No PCT/US2025/054539 Applicant ALLEN INSTITUTE Inventor GORE, Bryan
Artificial expression constructs for modulating gene expression in targeted central nervous system cell types are described. The artificial expression constructs can be used in the assessment and/or treatment of epileptic disorders.
2.WO/2026/102372GENOMIC DNA AMPLIFICATION AND BARCODING
WO - 15.05.2026
Int.Class C12Q 1/6855
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6844Nucleic acid amplification reactions
6853using modified primers or templates
6855Ligating adaptors
 Appl.No PCT/US2025/054759 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY Inventor GEILER-SAMEROTTE, Kerry
. In the first step of amplification, primers are employed that that bind a target sequence; and post-amplification, a barcoded primer is ligated onto the newly amplified double-stranded DNA, the barcoded primer having a free end that allows the attachment of additional barcodes. This strategy provides for improved amplification efficiency over methods previously used in the art.
3.WO/2026/102462ENGINEERED CELLS FOR TREATING DIABETES
WO - 15.05.2026
Int.Class A61K 35/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
48Reproductive organs
54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
545Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
 Appl.No PCT/US2025/055010 Applicant CITY OF HOPE Inventor YEE, Jiing-Kuan
, genetically engineered human pluripotent stem cells, beta cells derived from genetically engineered human pluripotent stem cells, compositions, and cell aggregates, and methods of treating diabetes. The human pluripotent stem cells and beta cells provided herein including embodiments thereof may be genetically modified to express exogenous genes and/or inactivate endogenous genes.
4.WO/2026/099477DOSING OF OLIGONUCLEOTIDE DRUGS FOR INHALATION
WO - 15.05.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/EP2025/082448 Applicant RNATICS GMBH Inventor RABE, Klaus F.
The present invention relates to a formulation comprising an oligonucleotide drug which is an antagonist of microRNA-21 as an active agent for administration to a human subject in need thereof by inhalation.
5.WO/2026/099582CONSTRUCTS FOR RNA EXPRESSION
WO - 15.05.2026
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
 Appl.No PCT/GB2025/052425 Applicant OXFORD UNIVERSITY INNOVATION LIMITED Inventor HUGHES, James, Raymond
Provided are synthetic constructs for providing an enhancer or variant thereof as a promoter to drive RNA expression, as well as nucleic acids, vectors, and cells encoding or comprising said constructs. Associated methods and pharmaceutical compositions for use in therapy are also provided herein.
6.WO/2026/098802ULK1 INHIBITOR FOR THE TREATMENT OF A NEURODEGENERATIVE DISEASE
WO - 15.05.2026
Int.Class A61K 31/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
 Appl.No PCT/EP2025/070130 Applicant ETH ZÜRICH Inventor GEREZ, Juan Atilio
The invention relates to a ULK1 inhibitor for use in the treatment of a human or mammalian patient being diagnosed for, suffering from, or being at risk of developing a neurodegenerative disease, or in the prevention of such condition.
7.WO/2026/097917BISPECIFIC ANTIBODY AGAINST TL1A AND IL-23 AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No PCT/CN2025/108267 Applicant BEIJING VDJBIO CO., LTD Inventor LI, Dongxia
Provided is a bispecific antibody, comprising: a first domain that specifically binds TNF-like ligand 1a (TL1A), and a second domain that specifically binds interleukin-23 (IL-23). Also provided is a method of using the bispecific antibodies for the treatment or prevention of diseases associated with TL1A and/or IL-23.
8.WO/2026/098007NANOBODY TARGETING IL-23A AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
 Appl.No PCT/CN2025/116820 Applicant ZHANG, Fan Inventor ZHANG, Fan
The present invention belongs to the technical field of biomedicine. Provided are a nanobody targeting IL-23A and the use thereof. The nanobody comprises a framework region and a complementarity determining region, wherein the framework region comprises FR-H1, FR-H2, FR-H3 and FR-H4 having amino acid sequences as shown in SEQ ID NOs. 4-7, respectively; and the complementary determining region comprises CDR-H1, CDR-H2 and CDR-H3 having amino acid sequences as shown in SEQ ID NOs. 1-3, respectively. The nanobody can be used in the preparation of an antibody drug targeting IL-23A, which is capable of treating related diseases by means of binding to IL-23A.
9.WO/2026/097617RECOMBINANT HIRUDIN WITH TYROSINE SULFATION, PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 14/815
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
81Protease inhibitors
815from leeches, e.g. hirudin, eglin
 Appl.No PCT/CN2024/133290 Applicant WUHAN YUANQI HE SHENG TECHNOLOGIAE SOCIETAS LIMITATA Inventor XING, Junqiao
The present invention belongs to the technical field of genetic engineering. Provided are a recombinant hirudin with tyrosine sulfation, a preparation method therefor and the use thereof. In order to improve the safety and synthesis yield of recombinant hirudin, and reduce the production cost, a recombinant hirudin with tyrosine sulfation is prepared by means of an algae expression vector.
10.WO/2026/097752RNA EDITING METHOD AND REAGENT
WO - 15.05.2026
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
 Appl.No PCT/CN2025/081795 Applicant SUN YAT-SEN UNIVERSITY Inventor ZHANG, Rui
The present invention relates to an RNA editing method and a reagent. The method uses a type III CRISPR complex and introduces a bulge loop structure of at least one base onto gRNA to edit a target RNA molecule. The method can bypass the characteristics of a 6-nucleotide-based cleavage rule, thereby enabling cleavage and ligation of RNA bases that are not multiples of 6 nucleotides.
# -